Core Insights - Boundless Bio is advancing its clinical programs targeting oncogene-amplified cancers, specifically through the BBI-355 and BBI-825 combination in the POTENTIATE trial, which is now open for enrollment [1][7] - The company is on track to submit an investigational new drug (IND) application for BBI-940 in the first half of 2026, aiming to deliver initial proof-of-concept clinical data within its existing cash runway timeline [1][7] - As of June 30, 2025, Boundless Bio has $127 million in cash, which is expected to support operations into the first half of 2028 [1][7] Research and Development Highlights - The POTENTIATE clinical trial is focused on evaluating the combination of BBI-355, a selective CHK1 inhibitor, and BBI-825, a selective RNR inhibitor, for their synergistic anti-tumor activity [5][7] - BBI-940 is being developed as a first-in-class orally bioavailable selective Kinesin degrader, with IND-enabling studies currently underway [5][7] Financial Performance - For the second quarter of 2025, research and development expenses were $12.2 million, a decrease from $14.7 million in the same period of 2024 [7][9] - General and administrative expenses were $4.8 million for the second quarter of 2025, slightly up from $4.7 million in the same period of 2024 [7][9] - The net loss for the second quarter of 2025 was $15.7 million, compared to a net loss of $17.0 million for the same period in 2024 [7][9]

Financial Data and Key Metrics Changes - The company ended Q1 with $138 million on the balance sheet, projecting cash to last until February 2028, allowing for continued clinical development of its programs [57] - The company expects meaningful readouts from the combination of its two lead programs and the new program in the clinic within the cash runway timeframe [58] Business Line Data and Key Metrics Changes - The company has three candidates in development, focusing on synthetic lethality in oncogene amplified tumors, with two lead programs being a selective Check1 inhibitor and a selective RNR inhibitor [10][15] - The company is exploring a combination therapy approach to enhance efficacy while managing safety concerns, with plans to dose both compounds weekly instead of daily [17][23] Market Data and Key Metrics Changes - The company operates in a niche market addressing oncogene amplification, which affects approximately 25% of all cancer patients, representing a significant unmet medical need [2][60] - The competitive landscape is evolving, with major pharmaceutical companies beginning to explore the e cDNA space, indicating growing interest in this area [52][54] Company Strategy and Development Direction - The company aims to leverage its proprietary SpyGlass platform to identify novel targets and develop therapies specifically for cancers driven by e cDNA [6][9] - The strategic focus includes expanding its pipeline with additional novel targets while ensuring efficient use of capital to sustain operations and development [66] Management's Comments on Operating Environment and Future Outlook - Management acknowledges the challenging biotech market environment but emphasizes the importance of demonstrating clinical efficacy to gain investor confidence [60][64] - The company is optimistic about its innovative approach and the potential for significant advancements in cancer treatment, positioning itself as a leader in the e cDNA space [64][66] Other Important Information - The company has developed a proprietary diagnostic tool called Echo to detect e cDNA, which integrates with standard multi-gene panels, enhancing its clinical studies [49][50] - The company is in the IND enabling phase for its new program targeting a novel kinesin oral degrader, with plans to initiate patient dosing in the first half of next year [45][46] Q&A Session Summary Question: What is the company's cash position and runway? - The company ended Q1 with $138 million, projecting cash to last until February 2028, allowing for continued clinical development of its programs [57] Question: What are the next steps for the combination therapy? - The company is awaiting FDA feedback on the combination therapy and plans to initiate patient dosing in the next couple of months [39][40] Question: How does the company view competition in the e cDNA space? - The company recognizes growing interest from major pharma companies in the e cDNA area but believes it remains a leader due to its focused research and proprietary platform [52][54] Question: What is the company's strategy for future target identification? - The company plans to continue identifying novel targets and drugs while being mindful of macroeconomic conditions affecting capital availability [66]

Company Overview - Boundless Bio is a clinical-stage oncology company focused on developing therapies for patients with oncogene amplified cancers, addressing a significant unmet medical need [3] - The company is investigating extrachromosomal DNA (ecDNA), which is implicated in oncogene amplification in 14% to 17% of cancer patients [3] Product Development - Boundless Bio is developing its first ecDNA-directed therapeutic candidate, BBI-355, an oral inhibitor of checkpoint kinase 1 (CHK1), currently in a Phase 1/2 clinical trial [3] - The next therapeutic candidate, BBI-825, is an oral inhibitor of ribonucleotide reductase (RNR) and has been evaluated in a Phase 1/2 clinical trial for cancer patients with resistance gene amplifications [3] - The company is also conducting IND-enabling studies for BBI-940, a potentially first-in-class orally bioavailable Kinesin degrader [3] Upcoming Events - Zachary Hornby, President and CEO of Boundless Bio, will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference on June 9, 2025, at 9:20 a.m. ET [1][2]

Summary of Boundless Bio (BOLD) Update / Briefing May 27, 2025 Company Overview - **Company**: Boundless Bio (BOLD) - **Focus**: Development of therapies for oncogene amplified cancers, particularly through the study of extrachromosomal DNA (e cDNA) biology [5][6] Key Industry Insights - **Industry Context**: The biotechnology sector is facing challenges in securing funding and establishing differentiation due to a proliferation of competitor compounds [38] - **Market Considerations**: The company is prioritizing first-in-class drugs against innovative biological targets to maintain a competitive edge [38] Core Points and Arguments 1. **Portfolio Prioritization**: Boundless Bio has decided to discontinue all current arms of the BBI-355 clinical trial due to clinical observations and market considerations, shifting focus to a new trial arm evaluating BBI-355 in combination with BBI-825 [3][4] 2. **Workforce Reduction**: The company has streamlined operations, reducing its workforce by approximately 20 positions, representing about one-third of its staff, to extend its cash runway into the first half of 2028 [4][36] 3. **Development Candidates**: BBI-940 has been declared a development candidate for the novel kinesin oral degrader program, with an IND filing expected in the first half of 2026 [4][36] 4. **Clinical Findings**: BBI-355 has shown evidence of anti-tumor activity but has a narrow therapeutic index due to on-target hematologic toxicity, leading to the decision not to advance certain clinical arms [12][14] 5. **Combination Therapy Rationale**: The combination of BBI-355 and BBI-825 is believed to provide synergistic anti-tumor activity while minimizing hematologic toxicity, with plans to initiate clinical development in 2025 [28][29] Additional Important Content - **Scientific Basis**: The company has developed a proprietary SpyGlass platform to identify new targets in e cDNA biology, leading to the discovery of three druggable targets that may be synthetic lethal in oncogene amplified tumors [5][6] - **Clinical Strategy**: The combination of BBI-355 and BBI-825 is expected to leverage the unique mechanisms of both drugs, potentially overcoming the limitations observed when each is used independently [20][28] - **Preclinical Data**: BBI-940 has demonstrated potent anti-tumor activity in preclinical models, with favorable pharmacokinetics and oral bioavailability [33][34] - **Future Outlook**: The company is focused on achieving important clinical readout milestones and believes it is uniquely positioned with proprietary selective inhibitors [39][70] Financial Guidance - **Cash Runway**: The changes in operations and portfolio prioritization are expected to extend the company's cash runway into the first half of 2028, aligning with anticipated clinical readouts [36][37]

Core Insights - Boundless Bio is focusing on the novel combination therapy of BBI-355 and BBI-825, along with the new development candidate BBI-940 for its kinesin program, aiming to optimize its portfolio for patient impact and long-term value creation [1][3][11] - The company's operating runway has been extended into the first half of 2028, allowing for expected proof-of-concept clinical readouts for each program [1][3][9] BBI-355 and BBI-825 Programs - The company has decided to discontinue the current monotherapy and combination arms of BBI-355 in the POTENTIATE clinical trial due to its narrow therapeutic index and associated hematological toxicity [4][6] - BBI-825 was not advanced in the STARMAP clinical trial due to a lack of dose proportional pharmacokinetic exposure, but there is a strong rationale for combining BBI-355 and BBI-825 for synergistic anti-tumor activity without overlapping toxicity [5][6] - Plans are in place to evaluate the combination of BBI-355 and BBI-825 in the POTENTIATE clinical trial, targeting initiation in the second half of 2025 [6][7] Kinesin Program - BBI-940 has been declared as the development candidate for the novel kinesin program, targeting a previously undrugged kinesin involved in DNA segregation [8] - The company expects to submit an Investigational New Drug (IND) application for BBI-940 in the first half of 2026 and deliver initial proof-of-concept clinical data within its extended cash runway timeline [8][9] Operational Update - Boundless Bio has streamlined its operations, resulting in approximately a one-third reduction of its workforce, which is expected to extend its cash runway into the first half of 2028 [9][10] - As of March 31, 2025, the company reported cash, cash equivalents, and short-term investments totaling $138.3 million, which will support its operations through anticipated clinical proof-of-concept readouts [9]

Core Insights - Smirnoff launched its new flavor, Electric Guava, at a vibrant event called Calle Electric in Miami, showcasing a blend of cultural expression and music [1][2] - The event featured a surprise debut of a new track by DJs Coco & Breezy, enhancing the overall experience of the new flavor [2] - Electric Guava is designed for easy sipping, combining guava and ginger flavors, and is priced at $12.99 for a 750 ml bottle [3] Product Details - Electric Guava has a 25% alcohol by volume (ABV) and is available nationwide, with a limited supply encouraging consumers to purchase quickly [3][4] - The classic Spicy Tamarind flavor is also highlighted, priced similarly at $12.99 for a 750 ml bottle but with a higher ABV of 30% [4] - Smirnoff continues to innovate with its product offerings, including ready-to-serve beverages and limited editions that cater to evolving consumer tastes [10] Brand Strategy - The introduction of Electric Guava reflects Smirnoff's commitment to celebrating cultural flavors, particularly those rooted in Hispanic culture [4] - The brand emphasizes diversity and inclusion, aiming to create enjoyable experiences for all consumers aged 21 and above [8] - Smirnoff has a long history of adapting to consumer preferences, having launched various iconic products since its inception in 1864 [7][10]

Core Viewpoint - Boundless Bio, Inc. (BOLD) has received a Zacks Rank 2 (Buy) upgrade, indicating a positive trend in earnings estimates which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Price Impact - The Zacks rating system is based on changes in earnings estimates, which have a strong correlation with near-term stock price movements [4][6]. - Rising earnings estimates for Boundless Bio suggest an improvement in the company's underlying business, which could lead to higher stock prices as investors respond positively [5][10]. Recent Performance and Projections - Boundless Bio is projected to earn -$3.01 per share for the fiscal year ending December 2025, reflecting a year-over-year change of 21.8% [8]. - Over the past three months, the Zacks Consensus Estimate for Boundless Bio has increased by 10%, indicating a positive revision trend [8]. Zacks Rating System Overview - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with only the top 20% receiving a 'Strong Buy' or 'Buy' rating [9][10]. - The Zacks Rank 2 upgrade places Boundless Bio in the top 20% of Zacks-covered stocks, suggesting potential for market-beating returns in the near term [10].

[PART I. FINANCIAL INFORMATION](index=9&type=section&id=PART%20I.%20FINANCIAL%20INFORMATION) [Financial Statements (Unaudited)](index=9&type=section&id=Item%201.%20Financial%20Statements%20(Unaudited)) This section presents Boundless Bio, Inc.'s unaudited condensed financial statements, including balance sheets, statements of operations, stockholders' equity, and cash flows, for the three months ended March 31, 2025 and 2024, reporting a net loss of **$15,758 thousand** for Q1 2025 [Condensed Balance Sheets](index=9&type=section&id=Condensed%20Balance%20Sheets) Total assets decreased to **$191,242 thousand** as of March 31, 2025, from **$206,409 thousand** at year-end 2024, primarily due to reduced cash and cash equivalents, while total stockholders' equity declined to **$136,592 thousand** Condensed Balance Sheet Highlights (in thousands) | Account | March 31, 2025 (unaudited) | December 31, 2024 | | :--- | :--- | :--- | | Cash and cash equivalents | $15,117 | $26,587 | | Short-term investments | $123,136 | $125,527 | | **Total current assets** | **$140,364** | **$154,390** | | **Total assets** | **$191,242** | **$206,409** | | Total current liabilities | $6,338 | $8,135 | | **Total liabilities** | **$54,650** | **$55,767** | | **Total stockholders' equity** | **$136,592** | **$150,642** | [Condensed Statements of Operations and Comprehensive Loss](index=10&type=section&id=Condensed%20Statements%20of%20Operations%20and%20Comprehensive%20Loss) The company reported a net loss of **$15,758 thousand** for the three months ended March 31, 2025, an increase from **$15,430 thousand** in the prior year, driven by higher general and administrative expenses Condensed Statement of Operations (in thousands, except per share data) | Metric | Three Months Ended March 31, 2025 | Three Months Ended March 31, 2024 | | :--- | :--- | :--- | | Research and development | $12,138 | $13,129 | | General and administrative | $5,203 | $3,754 | | **Total operating expenses** | **$17,341** | **$16,883** | | Loss from operations | $(17,341) | $(16,883) | | **Net loss** | **$(15,758)** | **$(15,430)** | | Net loss per share, basic and diluted | $(0.71) | $(12.27) | [Condensed Statements of Cash Flows](index=12&type=section&id=Condensed%20Statements%20of%20Cash%20Flows) Net cash used in operating activities was **$14,530 thousand** for Q1 2025, a decrease from **$15,776 thousand** in the prior year, with **$3,060 thousand** provided by investing activities and no financing activities Condensed Statement of Cash Flows (in thousands) | Cash Flow Activity | Three Months Ended March 31, 2025 | Three Months Ended March 31, 2024 | | :--- | :--- | :--- | | Net cash used in operating activities | $(14,530) | $(15,776) | | Net cash provided by investing activities | $3,060 | $18,137 | | Net cash used in financing activities | $0 | $(924) | | **Net (decrease)/increase in cash, cash equivalents, and restricted cash** | **$(11,470)** | **$1,437** | [Notes to Condensed Financial Statements](index=13&type=section&id=Notes%20to%20Condensed%20Financial%20Statements) The notes detail the company's financial statements, including its April 2024 IPO which raised **$87,700 thousand** in net proceeds, and its current cash position of **$138,300 thousand** expected to fund operations for at least twelve months - The company completed its Initial Public Offering (IPO) on April 2, 2024, selling 6,250,000 shares at $16.00 per share, resulting in net proceeds of approximately **$87,700 thousand**[29](index=29&type=chunk) - As of March 31, 2025, the company had **$138,300 thousand** in cash, cash equivalents, and short-term investments, which it believes is sufficient to fund operations for at least the next twelve months[33](index=33&type=chunk) - The company has an accumulated deficit of **$217,200 thousand** as of March 31, 2025, and expects to incur significant losses for the foreseeable future[34](index=34&type=chunk) - In April 2025, the company entered into an Open Market Sale Agreement to sell up to **$14,500 thousand** of its common stock in "at the market" offerings; no shares have been sold under this agreement as of the report date[79](index=79&type=chunk)[80](index=80&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=25&type=section&id=Item%202.%20Management's%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses the company's financial condition and operations, highlighting its clinical-stage oncology focus, lead candidate BBI-355 in Phase 1/2 trials, a net loss of **$15,758 thousand** for Q1 2025, and **$138,300 thousand** in cash and investments expected to fund operations into 2027 - The company's lead ecDTx, BBI-355, is in a Phase 1/2 clinical trial (POTENTIATE) for patients with oncogene amplified cancers, with preliminary safety and antitumor activity data expected in **H2 2025**[85](index=85&type=chunk) - The company made a strategic decision in December 2024 to discontinue dose escalation of its BBI-825 STARMAP clinical trial[86](index=86&type=chunk) - The company expects to select a development candidate for its Kinesin program by **mid-2025** and submit an IND in the **first half of 2026**[87](index=87&type=chunk) - As of March 31, 2025, the company had **$138,300 thousand** in cash, cash equivalents, and short-term investments, which is believed to be sufficient to fund operations into **2027**[92](index=92&type=chunk)[118](index=118&type=chunk) R&D Expense Breakdown (in thousands) | Program | Three Months Ended March 31, 2025 | Three Months Ended March 31, 2024 | | :--- | :--- | :--- | | BBI-355 | $2,954 | $2,231 | | BBI-825 | $1,146 | $2,136 | | Other development programs | $801 | $1,220 | | **Total direct program costs** | **$4,901** | **$5,587** | | Indirect program costs | $7,237 | $7,542 | | **Total R&D expenses** | **$12,138** | **$13,129** | - R&D expenses decreased by **$1,000 thousand** year-over-year, primarily due to reduced spending on the BBI-825 trial and lower outside services costs, partially offset by increased facilities-related expenses from a new headquarters[113](index=113&type=chunk) - G&A expenses increased by **$1,400 thousand** year-over-year, driven by higher facilities costs, stock-based compensation, and costs associated with operating as a public company[114](index=114&type=chunk) [Quantitative and Qualitative Disclosures About Market Risk](index=38&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) As a smaller reporting company, Boundless Bio is not required to provide quantitative and qualitative disclosures about market risk - As a smaller reporting company, Boundless Bio is not required to provide quantitative and qualitative disclosures about market risk[136](index=136&type=chunk) [Controls and Procedures](index=38&type=section&id=Item%204.%20Controls%20and%20Procedures) Management concluded that the company's disclosure controls and procedures were effective as of March 31, 2025, and as a newly public company, it is not yet required to evaluate internal control over financial reporting - Management concluded that the company's disclosure controls and procedures were effective as of the end of the period covered by this report[137](index=137&type=chunk) - The company is not yet required to have management evaluate the effectiveness of its internal control over financial reporting due to the transition period for newly public companies[138](index=138&type=chunk) [PART II. OTHER INFORMATION](index=40&type=section&id=PART%20II.%20OTHER%20INFORMATION) [Legal Proceedings](index=40&type=section&id=Item%201.%20Legal%20Proceedings) The company is not currently a party to any material pending legal proceedings and is unaware of any contemplated governmental proceedings - There are no material pending legal proceedings to which the company is a party[140](index=140&type=chunk) [Risk Factors](index=40&type=section&id=Item%201A.%20Risk%20Factors) No material changes have occurred in the risk factors since the filing of the Annual Report on Form 10-K for the year ended December 31, 2024 - No material changes have occurred in the risk factors since the filing of the Annual Report on Form 10-K for the year ended December 31, 2024[141](index=141&type=chunk) [Unregistered Sales of Equity Securities and Use of Proceeds](index=40&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) The company reports no unregistered sales of equity securities during the period, and there has been no material change in the planned use of IPO proceeds - There were no unregistered sales of equity securities in the quarter[142](index=142&type=chunk) - The planned use of proceeds from the IPO has not materially changed[143](index=143&type=chunk) [Other Information](index=40&type=section&id=Item%205.%20Other%20Information) A Rule 10b5-1 trading plan for former Chief Business Officer Neil Abdollahian was terminated on January 29, 2025, with no sales occurring prior to termination - On January 29, 2025, a Rule 10b5-1 trading plan for former Chief Business Officer Neil Abdollahian was terminated[150](index=150&type=chunk)

[Business and Operational Highlights](index=1&type=section&id=Business%20and%20Operational%20Highlights) Boundless Bio anticipates BBI-355 proof-of-concept data in H2 2025 and a Kinesin program IND filing in H1 2026 - Initial proof-of-concept data from the BBI-355 Phase 1/2 POTENTIATE trial in patients with oncogene-amplified cancers is anticipated in the **second half of 2025**[1](index=1&type=chunk)[2](index=2&type=chunk) - The novel Kinesin program is on track to nominate a development candidate by **mid-2025**, with an Investigational New Drug (IND) submission planned for the **first half of 2026**[1](index=1&type=chunk)[3](index=3&type=chunk) - Preclinical data for BBI-825, presented at the AACR Annual Meeting, suggested potential to delay or prevent acquired resistance in colorectal cancer models when combined with RAS targeting inhibitors[4](index=4&type=chunk) [First Quarter 2025 Financial Results](index=2&type=section&id=First%20Quarter%202025%20Financial%20Results) Boundless Bio reported a Q1 2025 net loss of **$15.8 million**, with **$138.3 million** cash supporting operations into 2027 - The company maintains a strong cash position with **$138.3 million** in cash, cash equivalents, and short-term investments as of March 31, 2025, providing an operating runway into **2027**[1](index=1&type=chunk)[8](index=8&type=chunk) Q1 2025 Financial Highlights (vs. Q1 2024) | Metric | Q1 2025 | Q1 2024 | | :--- | :--- | :--- | | R&D Expenses | $12.1 million | $13.1 million | | G&A Expenses | $5.2 million | $3.8 million | | Net Loss | $15.8 million | $15.4 million | [Consolidated Financial Statements](index=4&type=section&id=Consolidated%20Financial%20Statements) Q1 2025 statements detail **$17.3 million** in operating expenses, a **$15.8 million** net loss, and **$191.2 million** in total assets Statement of Operations (Three Months Ended March 31, in thousands) | Line Item | 2025 (in thousands) | 2024 (in thousands) | | :--- | :--- | :--- | | Research and development | $12,138 | $13,129 | | General and administrative | $5,203 | $3,754 | | **Total operating expenses** | **$17,341** | **$16,883** | | Loss from operations | $(17,341) | $(16,883) | | Interest income | $1,585 | $1,421 | | **Net loss** | **$(15,758)** | **$(15,430)** | | Net loss per share | $(0.71) | $(12.27) | Balance Sheet Data (in thousands) | Line Item | March 31, 2025 (in thousands) | December 31, 2024 (in thousands) | | :--- | :--- | :--- | | Cash, cash equivalents, and short-term investments | $138,253 | $152,114 | | Total assets | $191,242 | $206,409 | | Total liabilities | $54,650 | $55,767 | | Total stockholders' equity | $136,592 | $150,642 | [Company Overview and Forward-Looking Statements](index=2&type=section&id=Company%20Overview%20and%20Forward-Looking%20Statements) Boundless Bio, an oncology company targeting ecDNA in amplified tumors, notes forward-looking statements are subject to inherent drug development risks - The company's research focuses on extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in **14% to 17%** of cancer patients[6](index=6&type=chunk) - The company's lead ecDNA-directed therapeutic candidate (ecDTx) is **BBI-355**, an oral inhibitor of checkpoint kinase 1 (**CHK1**)[6](index=6&type=chunk) - Forward-looking statements are subject to risks including the unproven nature of the company's novel approach, potential clinical trial delays, and regulatory uncertainties[7](index=7&type=chunk)[9](index=9&type=chunk)

Core Insights - Boundless Bio is focused on developing therapies for oncogene-amplified cancers, with ongoing clinical trials and promising data expected in the near future [2][3][7] Research and Development Highlights - The BBI-355 Phase 1/2 POTENTIATE trial is currently enrolling patients, with initial proof-of-concept data anticipated in the second half of 2025 [1][3] - A novel Kinesin program is on track for a development candidate nomination by mid-2025, with an IND filing planned for the first half of 2026 [1][4] - Preclinical data for the RNR inhibitor BBI-825 suggests it may delay or prevent acquired resistance in colorectal cancer models [5] Financial Performance - As of March 31, 2025, the company reported a cash position of $138.3 million, providing operational runway into 2027 [1][8] - Research and Development expenses for Q1 2025 were $12.1 million, a decrease from $13.1 million in Q1 2024 [8][12] - General and Administrative expenses increased to $5.2 million in Q1 2025 from $3.8 million in Q1 2024 [8][12] - The net loss for Q1 2025 was $15.8 million, compared to a net loss of $15.4 million in the same period of 2024 [8][12]